Published in Eur Arch Otorhinolaryngol on June 17, 2011
Large cell neuroendocrine carcinoma of the head and neck: a distinct clinicopathologic entity. Eur Arch Otorhinolaryngol (2014) 0.78
Cutaneous and Subcutaneous Metastases From Atypical Laryngeal Carcinoids: Case Report and Review of the Literature. Medicine (Baltimore) (2016) 0.75
Laryngeal Neuroendocrine Carcinomas: A Retrospective Study of 14 Cases. Biomed Res Int (2015) 0.75
Neuroendocrine neoplasms of the larynx: an overview. Head Neck (2009) 1.92
Neuroendocrine neoplasms of the larynx: advances in identification, understanding, and management. Oral Oncol (2006) 1.70
Terminology and classification of neuroendocrine neoplasms of the larynx. Laryngoscope (2011) 1.03
Primary and secondary small cell neuroendocrine carcinoma of the larynx: a review. Head Neck (2008) 0.98
Large cell neuroendocrine carcinoma of the larynx: definition of an entity. Head Neck Pathol (2010) 0.96
Neuroendocrine neoplasms of the larynx: diagnosis, treatment and prognosis. ORL J Otorhinolaryngol Relat Spec (2002) 0.87
Neuroendocrine carcinomas of the larynx: what do the different histologic types really mean? Eur Arch Otorhinolaryngol (2010) 0.86
Endoscopic CO2 laser surgery for an atypical carcinoid tumor of the epiglottis masquerading as a supraglottic cyst. Head Neck (2005) 0.80
Unusual presentation of large-cell poorly differentiated neuroendocrine carcinoma of the epiglottis. J Clin Oncol (2010) 0.79
Treatment with carbon dioxide laser of painful skin metastases from a laryngeal neuroendocrine carcinoma. Clin Exp Dermatol (2009) 0.79
Selective neck dissection (IIA, III): a rational replacement for complete functional neck dissection in patients with N0 supraglottic and glottic squamous carcinoma. Laryngoscope (2008) 0.76
Laser excision of a typical carcinoid tumor of the larynx: a case report. Kulak Burun Bogaz Ihtis Derg (2010) 0.75
Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis (2012) 2.58
The future of the TNM staging system in laryngeal cancer: time for a debate? Eur Arch Otorhinolaryngol (2008) 2.58
Paragangliomas of the head and neck. Oral Oncol (2004) 2.47
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother (2008) 2.38
Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck (2011) 2.30
Vascularized tissue to reduce fistula following salvage total laryngectomy: a systematic review. Laryngoscope (2014) 2.21
Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother (2012) 2.17
MR imaging of the spleen: spectrum of abnormalities. Radiographics (2005) 2.16
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol (2009) 2.08
Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother (2005) 2.05
Human papillomavirus-positive basaloid squamous cell carcinomas of the upper aerodigestive tract: a distinct clinicopathologic and molecular subtype of basaloid squamous cell carcinoma. Hum Pathol (2010) 2.01
High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol (2011) 2.00
Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck (2011) 1.97
Neuroendocrine neoplasms of the larynx: an overview. Head Neck (2009) 1.92
Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy (2003) 1.85
Neuroendocrine neoplasms of the larynx: advances in identification, understanding, and management. Oral Oncol (2006) 1.70
Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother (2005) 1.69
Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg (2008) 1.68
KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. Antimicrob Agents Chemother (2008) 1.67
Adenosquamous carcinoma of the head and neck: relationship to human papillomavirus and review of the literature. Head Neck Pathol (2011) 1.61
Thyroglossal duct cyst: personal experience and literature review. Auris Nasus Larynx (2007) 1.57
Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. Oral Oncol (2012) 1.55
A retrospective comparison of 2 methods of intraoperative margin evaluation during partial nephrectomy. J Urol (2008) 1.49
Current treatment options for recurrent nasopharyngeal cancer. Eur Arch Otorhinolaryngol (2010) 1.48
Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. Med Mycol (2010) 1.45
Sinonasal tumors: a clinicopathologic update of selected tumors. Eur Arch Otorhinolaryngol (2012) 1.43
Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope (2010) 1.42
An outline of the history of head and neck oncology. Oral Oncol (2007) 1.42
Do pathologic and molecular analyses of neck dissection specimens justify the preservation of level IV for laryngeal squamous carcinoma with clinically negative neck? J Am Coll Surg (2005) 1.39
Adrenal masses: mr imaging features with pathologic correlation. Radiographics (2004) 1.38
Prognostic significance of microscopic and macroscopic extracapsular spread from metastatic tumor in the cervical lymph nodes. Oral Oncol (2002) 1.38
Transoral laser microsurgery (TLM) +/- adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope (2009) 1.37
Planned neck dissection for patients with complete response to chemoradiotherapy: a concept approaching obsolescence. Head Neck (2010) 1.34
Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck (2010) 1.34
ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res (2011) 1.34
Advances and applications of oral cancer basic research. Oral Oncol (2011) 1.33
Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol (2005) 1.33
Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother (2012) 1.31
Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother (2009) 1.31
Management of sarcomas of the head and neck in adults. Oral Oncol (2003) 1.31
Evidence-based review of treatment options for patients with glottic cancer. Head Neck (2011) 1.30
Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol (2009) 1.29
Neck disease and distant metastases. Oral Oncol (2003) 1.27
Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol (2010) 1.26
Elective and therapeutic selective neck dissection. Oral Oncol (2005) 1.26
Human papillomavirus infections in laryngeal cancer. Head Neck (2011) 1.22
Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med (2014) 1.21
Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck (2010) 1.20
Surgical margins in head and neck cancer: a contemporary review. Head Neck (2012) 1.19
Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck (2008) 1.18
Papillary squamous cell carcinoma of the head and neck: clinicopathologic and molecular features with special reference to human papillomavirus. Am J Surg Pathol (2013) 1.18
Esthesioneuroblastoma and cervical lymph node metastases: clinical and therapeutic implications. Acta Otolaryngol (2002) 1.16
Management of nasal bone fractures. Am J Otolaryngol (2005) 1.16
MRI of adrenal and extraadrenal pheochromocytoma. AJR Am J Roentgenol (2005) 1.16
Neck dissection: then and now. Auris Nasus Larynx (2006) 1.14
Aggressive variants of papillary thyroid carcinoma. Head Neck (2010) 1.13
Routine drainage after thyroid surgery--a meta-analysis. J Surg Oncol (2007) 1.13
Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options. Head Neck (2011) 1.13
Jugular and vagal paragangliomas: Systematic study of management with surgery and radiotherapy. Head Neck (2012) 1.13
Cutaneous squamous cell carcinoma of the head and neck metastasizing to the parotid gland--a review of current recommendations. Head Neck (2010) 1.12
Management of malignant sublingual salivary gland tumors. Oral Oncol (2004) 1.11
Grisel's syndrome in head and neck practice. Oral Oncol (2005) 1.11
A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. Int J Cancer (2012) 1.11
Utility of high molecular weight cytokeratins, but not p63, in the differential diagnosis of neuroendocrine and basaloid carcinomas of the head and neck. Hum Pathol (2008) 1.11
Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncol (2012) 1.10
Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy (2011) 1.10
The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncol (2011) 1.09
Retropharyngeal lymph node metastases in head and neck malignancies. Head Neck (2010) 1.09
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun (2008) 1.09